FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164367827> ?p ?o ?g. }

• W3164367827 endingPage "e229" @default.
• W3164367827 startingPage "e228" @default.
• W3164367827 abstract "We thank Makoto Kosaka and colleagues for their insightful comments on the report of our TPExtreme (TPEx) regimen in recurrent and metastatic head and neck cancer. 1 Guigay J Aupérin A Fayette J et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021; 22: 463-475 Summary Full Text Full Text PDF PubMed Scopus (8) Google Scholar We recognise that other trials of taxane-based treatments, such as the paclitaxel, carboplatin, and cetuximab regimen, 2 Tahara M Kiyota N Yokota T et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018; 29: 1004-1009 Summary Full Text Full Text PDF PubMed Scopus (23) Google Scholar have confirmed the good activity of such combinations, and their results are encouraging. However, only our TPEx regimen has now been examined in a large randomised trial, which was necessary to stringently assess efficacy and safety to define treatment standards. The TPEx regimen is accepted as a reference treatment for patients with PD-L1-negative head and neck cancer, and randomised comparisons with immune-checkpoint inhibitor-based regimens might be indicated in patients with low-level PD-L1 expression, but several questions remain, and Kosaka and colleagues raise three important points. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialAlthough the trial did not meet its primary endpoint, with no significant improvement in overall survival with TPEx versus EXTREME, the TPEx regimen had a favourable safety profile. The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment. Full-Text PDF Unresolved questions regarding the promise of the TPEx regimenWe read with interest the study by Joël Guigay and colleagues1 in The Lancet Oncology comparing four cycles of docetaxel, cisplatin, and cetuximab followed by cetuximab maintenance (TPex) versus platinum, fluorouracil, and cetuximab followed by cetuximab maintenance (EXTREME) in patients with recurrent or metastatic head and neck squamous-cell carcinoma. We applaud the authors' efforts, and think that several points deserve further discussion. Full-Text PDF" @default.
• W3164367827 created "2021-06-07" @default.
• W3164367827 creator A5008235770 @default.
• W3164367827 creator A5017985440 @default.
• W3164367827 creator A5037339388 @default.
• W3164367827 creator A5066640097 @default.
• W3164367827 creator A5080242944 @default.
• W3164367827 creator A5081937285 @default.
• W3164367827 date "2021-06-01" @default.
• W3164367827 modified "2023-10-02" @default.
• W3164367827 title "Unresolved questions regarding the promise of the TPEx regimen – Authors' reply" @default.
• W3164367827 cites W2790560905 @default.
• W3164367827 cites W3133699750 @default.
• W3164367827 cites W3134959030 @default.
• W3164367827 doi "https://doi.org/10.1016/s1470-2045(21)00293-x" @default.
• W3164367827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34087138" @default.
• W3164367827 hasPublicationYear "2021" @default.
• W3164367827 type Work @default.
• W3164367827 sameAs 3164367827 @default.
• W3164367827 citedByCount "3" @default.
• W3164367827 countsByYear W31643678272022 @default.
• W3164367827 countsByYear W31643678272023 @default.
• W3164367827 crossrefType "journal-article" @default.
• W3164367827 hasAuthorship W3164367827A5008235770 @default.
• W3164367827 hasAuthorship W3164367827A5017985440 @default.
• W3164367827 hasAuthorship W3164367827A5037339388 @default.
• W3164367827 hasAuthorship W3164367827A5066640097 @default.
• W3164367827 hasAuthorship W3164367827A5080242944 @default.
• W3164367827 hasAuthorship W3164367827A5081937285 @default.
• W3164367827 hasConcept C121608353 @default.
• W3164367827 hasConcept C126322002 @default.
• W3164367827 hasConcept C143998085 @default.
• W3164367827 hasConcept C2776530083 @default.
• W3164367827 hasConcept C2776694085 @default.
• W3164367827 hasConcept C2776833033 @default.
• W3164367827 hasConcept C2777511904 @default.
• W3164367827 hasConcept C2778239845 @default.
• W3164367827 hasConcept C2779998722 @default.
• W3164367827 hasConcept C2781190966 @default.
• W3164367827 hasConcept C2781413609 @default.
• W3164367827 hasConcept C2781451048 @default.
• W3164367827 hasConcept C526805850 @default.
• W3164367827 hasConcept C530470458 @default.
• W3164367827 hasConcept C71924100 @default.
• W3164367827 hasConceptScore W3164367827C121608353 @default.
• W3164367827 hasConceptScore W3164367827C126322002 @default.
• W3164367827 hasConceptScore W3164367827C143998085 @default.
• W3164367827 hasConceptScore W3164367827C2776530083 @default.
• W3164367827 hasConceptScore W3164367827C2776694085 @default.
• W3164367827 hasConceptScore W3164367827C2776833033 @default.
• W3164367827 hasConceptScore W3164367827C2777511904 @default.
• W3164367827 hasConceptScore W3164367827C2778239845 @default.
• W3164367827 hasConceptScore W3164367827C2779998722 @default.
• W3164367827 hasConceptScore W3164367827C2781190966 @default.
• W3164367827 hasConceptScore W3164367827C2781413609 @default.
• W3164367827 hasConceptScore W3164367827C2781451048 @default.
• W3164367827 hasConceptScore W3164367827C526805850 @default.
• W3164367827 hasConceptScore W3164367827C530470458 @default.
• W3164367827 hasConceptScore W3164367827C71924100 @default.
• W3164367827 hasFunder F4320311647 @default.
• W3164367827 hasFunder F4320333003 @default.
• W3164367827 hasIssue "6" @default.
• W3164367827 hasLocation W31643678271 @default.
• W3164367827 hasOpenAccess W3164367827 @default.
• W3164367827 hasPrimaryLocation W31643678271 @default.
• W3164367827 hasRelatedWork W1982849070 @default.
• W3164367827 hasRelatedWork W1991999512 @default.
• W3164367827 hasRelatedWork W2051573328 @default.
• W3164367827 hasRelatedWork W2085844047 @default.
• W3164367827 hasRelatedWork W2091007248 @default.
• W3164367827 hasRelatedWork W2095756161 @default.
• W3164367827 hasRelatedWork W2363732038 @default.
• W3164367827 hasRelatedWork W3012537123 @default.
• W3164367827 hasRelatedWork W3164367827 @default.
• W3164367827 hasRelatedWork W3165165741 @default.
• W3164367827 hasVolume "22" @default.
• W3164367827 isParatext "false" @default.
• W3164367827 isRetracted "false" @default.
• W3164367827 magId "3164367827" @default.
• W3164367827 workType "article" @default.